PharmaWatch: Pfizer’s Zirabev Approved by European Commission

Feb 20, 2019 | Biosimilars, Cancer, EU, Europe, Leading Pharma, Oncology, Pharma Watch


Zirabev is the company’s fifth biosimilar to be approved in Europe. To be sold under the trade name Zirabev, the treatment will be prescribed for certain advanced cancers: carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer (NSCLC), renal cancer and cervical cancer. Andreas Penk, MD, regional president oncology international developed markets, noted “Pfizer is dedicatd to increasing access to biosimilars for patients suffering from serious illnesses and helping create a more sustainable healthcare system.”